| Cat. No. |
Size |
Price |
Figures |
|---|
RP10221-0.5 mg
| 0.5 mg | $ 52.25 | MSDS: 20080716221525 (PDF)
References:
- Tryoen-Toth P, et al. Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors. J. Pharmacol. Exp. Ther. Apr 2005; 313(1): 410-421.
- Xie Z, et al. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol. Pharmacol. Oct 2005; 68(4): 1079-1086.
- Claude-Geppert PA, et al. Antagonist efficacy in MORS196L mutant is affected by the interaction between transmembrane domains of the opioid receptor. J. Pharmacol. Exp. Ther. Apr 2005; 313(1): 216-226.
|
|---|
| Full Name | |
Sequence
(three-letter code) | {d-PHE}{CYS}{TYR}{d-TRP}{ORN}{THR}{PEN}{THR}-NH2 |
|---|
| C-Terminal | NH2 |
|---|
| Chemical Bridge | Cys2-Pen7 |
|---|
| Description | NTB, depending on the dosage, could acts not only as an antagonist at delta but also as a noncompetitive antagonist for mu receptors, and NTB can act as an agonist for kappa2 receptors in rat cerebral cortex too. |
|---|
| Solubility | Soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weight out a smaller portion of the contents. |
|---|
| Formula | C50H67N11O11S2 |
|---|
| M.W. | 1062.3 |
|---|
| Cas | 103429-31-8 |
|---|
| Purity | > 95% |
|---|
| Storage | Storage at -20°C. Keep tightly closed. |
| Notes | Super µ antagonist. |
|---|
